In stockTesamorelin 10 mg
Lyophilized vial 10 mg
GHRH Analog
Out of stockGLP-1 Agonist
Presentation
Long-acting GLP-1 analog for research on incretin signaling and glycemic homeostasis.
Need help? Contact support.
Long-acting GLP-1 analog for research on incretin signaling and glycemic homeostasis.
Sealed vial: 2–8 °C short term; −20 °C for long-term storage. Protect from light and humidity.
Reconstituted vial: 2–8 °C. Indicative stability of 14–28 days depending on the peptide.
Avoid freeze-thaw cycles. Discard if turbidity or precipitate is observed.
Lyophilized vial 5 mg
Available presentations: 5 mg, 10 mg.
Packaged in a sealed vial with rubber septum, labeled with batch and analysis date.
How do I verify the purity of the vial?
Each batch is accompanied by a downloadable COA with ≥99% HPLC purity, ESI-MS identity and a traceable batch number. You can also verify the batch at /verificar-lote.
How long does shipping take in Mexico?
Orders ship the next business day and typically arrive within 24–72 h via national courier. Discreet packaging with cold gel when applicable.
Can I change the presentation?
Yes — if the product has multiple presentations (mg), they appear in the selector above. For sizes outside the catalog, contact us via WhatsApp.
Is this product for human consumption?
No. Products are Research Use Only (RUO), intended exclusively for in vitro scientific research and preclinical models.
Product intended solely for in vitro scientific research. Not fit for human or veterinary consumption.
Semaglutide is a long-acting synthetic GLP-1 analog used as a reference material in metabolic research. Its design enables controlled study of GLP-1R activation and its effects on incretin signaling, glucose homeostasis, satiety and energy balance. Peptide Life offers it lyophilized, with ≥99% HPLC purity, exclusively for in vitro scientific research.
Semaglutide binds the GLP-1 receptor and activates signaling pathways associated with glucose-dependent insulin secretion, glucagon modulation, gastric emptying and central satiety signals. Its long-acting profile facilitates analysis of receptor response and metabolic variables over time in experimental models.
The phase 3 STEP 1 trial, published in The New England Journal of Medicine in 2021, documented a mean 14.9% body-weight reduction at 68 weeks with Semaglutide 2.4 mg, versus 2.4% with placebo. These clinical results contextualize its relevance as a GLP-1 reference standard, although the product offered by Peptide Life is for research only and not for human or veterinary use.
| Parameter | Value |
|---|---|
| Name | Semaglutide |
| Classification | Selective GLP-1 receptor agonist |
| Presentation | Lyophilized vial 5 mg |
| Purity | ≥99% HPLC-UV 220 nm |
| Identity | ESI-MS ±0.1 Da |
| Storage | −20°C |
| Shelf life | ≥18 months |
| Use | Research use only (RUO) |
| Price | $2,100 MXN (VAT included) |
In stockLyophilized vial 10 mg
GHRH Analog
In stockLyophilized vial 10 mg
NNMT Inhibitor
Out of stockLyophilized vial 10 mg
The Triple Agonist